Please login to the form below

Not currently logged in
Email:
Password:

Depomed and Watson sign co-promotion deal

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.

Per the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year.

Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.

Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy.

According to a Market Research report, fluoroquinolone sales are expected to remain relatively constant to 2011. The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn) of global sales.

25th July 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....